With high-affinity TCR technology, Creative Biolabs is capable of identifying the candidate target tumor antigen and the sequence of tumor-specific TCR to create tumor-specific T cells. We have high qualified groups and advanced technologies to perform TCR engineering services covering every unit of manufacturing and delivery pipeline. From a tumor-reactive T cell or active anti-tumor T-cell antigens, the appropriate target sequence is introduced to modify T cells to target a broad range of tumors with improved specificity. With engineering TCR construction and a series of assay, such as transgene expression, TCR/CD3 stability, lymphocyte antigen reactivity and cytotoxicity, animal experiments, etc., we provide cGMP-compliant TCR products for preclinical and clinical trials.